Search results
For the journal "Clinical infectious diseases"Search results
For the journal "Clinical infectious diseases"
Diphtheria
Cluster of non-toxigenic Corynebacterium diphtheriae infective endocarditis and rising background C. diphtheriae cases—Seattle, Washington 2020-2023
Non-toxigenic Corynebacterium diphtheriae (C. diphtheriae), often associated with wounds, can rarely cause infective endocarditis (IE). Five patients with C. diphtheriae IE were identified within 12 months at a Seattle-based hospital system. We reviewed prior C. diphtheriae...
Rabies
Non-inferiority study of purified Vero rabies vaccine – serum free in three-dose and two-dose pre-exposure prophylaxis regimens in comparison with licensed rabies vaccines
A next-generation, serum-free, highly purified Vero cell rabies vaccine, PVRV-NG2, is in development. This multicenter, observer-blind, phase 3 study evaluated the immunogenicity and safety of PVRV-NG2, compared with two licensed rabies vaccines (purified Vero cell rabies vaccine [PVRV] and human diploid...
Rabies
Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free, Compared With Two Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized Controlled Phase III Trial
A next-generation Vero cell rabies vaccine (PVRV-NG2) was developed using the same Pitman–Moore strain as in the licensed purified Vero cell vaccine (PVRV; Verorab®) and the human diploid cell vaccine (HDCV; Imovax Rabies®). This dual-center, modified double-blind, phase III study in France...
Hepatitis B
Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration of Maternal Screening and Infant Post-vaccination Serologic Testing
Evaluation of the impact on mother-to-child transmission (MTCT) of a HBV-prevention program that incorporates maternal antiviral prophylaxis is hindered by the limited availability of real-world data. This study analyzed data on maternal HBV screening, neonatal immunization, and post-vaccination serologic...
Yellow Fever
Characterization and investigation of risk factors for Late-relapsing hepatitis after yellow fever
Late relapsing hepatitis after yellow fever (LHep-YF) during the convalescent phase of the disease has been described during recent yellow fever (YF) outbreaks in Brazil. LHep-YF is marked by the rebound in liver enzymes and non-specific clinical manifestations around 30-60 days after YF symptom onset....
